EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Access and pricing of medicines for patients with rare diseases in the European Union: an industry perspective. A 2025 update

Giovanni Tafuri, Andrea Bracco, Jens Grueger

Expert Review of Pharmacoeconomics & Outcomes Research · 2025

DOI: 10.1080/14737167.2025.2479131 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, 2025. Verfasst von Giovanni Tafuri und 2 weiteren Autor:innen. Beteiligte Einrichtung: Value, Access & Policy, Apellis International GmbH, Zug, Switzerland. Hauptthemen laut MEDLINE: Orphan Drug Production, Rare Diseases, Drug Industry, Health Services Accessibility. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: In a previous publication, we provided an overview of the current situation of patient access to orphan drugs in the European Union (EU), of the evolving rare disease policy landscape and recommendations for areas of improvement throughout the lifecycle of orphan drugs. This article aims to provide an update on evolving new policies impacting access to orphan drugs in the European Union from a health technology developer perspective. AREAS COVERED: We provide an update on the emerging competitiveness gap in the pharmaceutical sector between the EU and the United States. We discuss the latest developments of the European Commission's revision proposal of the EU's pharmaceutical legislation and the threats and opportunities of the new HTA Regulation with a focus on orphan drugs. Additionally, we present the latest policy updates from Germany and the United Kingdom impacting orphan drug developers. EXPERT OPINION: While our initial set of recommendations remains unchanged, the policy landscape for orphan drugs seems to be deteriorating both at the EU and at the Member State level.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Orphan Drug ProductionRare DiseasesDrug IndustryHealth Services AccessibilityHumansEuropean UnionHealth PolicyTechnology Assessment, BiomedicalUnited StatesDrug CostsEconomic CompetitionCosts and Cost AnalysisLegislation, Drug

Stichwörter der Autor:innen

Orphan drugsaccesshealth technology assessmentorphan drug regulationpharmaceutical legislationpricing and reimbursement

Autor:innen und Institutionen

  • Value, Access & Policy, Apellis International GmbH, Zug, Switzerland.
  • Market Access, Madrigal Pharmaceuticals, Zug, Switzerland.
  • The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington, Seattle, Washington, USA.
  • Boston Consulting Group Zurich, Healthcare Practice Area, Zurich, Switzerland.

Zitieren

APA

Tafuri, G., Bracco, A., & Grueger, J. (2025). Access and pricing of medicines for patients with rare diseases in the European Union: an industry perspective. A 2025 update. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2025.2479131

Vancouver

Tafuri G, Bracco A, Grueger J. Access and pricing of medicines for patients with rare diseases in the European Union: an industry perspective. A 2025 update. Expert Review of Pharmacoeconomics & Outcomes Research. 2025. doi:10.1080/14737167.2025.2479131

BibTeX
@article{Tafuri2025,
  author = {Tafuri, Giovanni and Bracco, Andrea and Grueger, Jens},
  title = {Access and pricing of medicines for patients with rare diseases in the European Union: an industry perspective. A 2025 update},
  journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
  year = {2025},
  doi = {10.1080/14737167.2025.2479131}
}
Kostenlos starten →